Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (411-420 of 651) with videos related to

Pageof 66
Sort By:
Blood|January 10, 2024
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signatureAnna Mathioudaki, Xizhe Wang, David Sedloev, et al.
Plos One|October 8, 2016
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid LeukemiaChristoph Schliemann, Joachim Gerss, Stefanie Wiebe, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Cytotherapy|March 27, 2019
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cellsLei Wang, Wenjie Gong, Sanmei Wang, et al.
Blood Advances|June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCTJoseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Journal of Medicinal Chemistry|March 19, 2013
Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factorChristian Schwöppe, Caroline Zerbst, Max Fröhlich, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Blood Vessels, Thrombosis & Hemostasis|December 3, 2025
Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkersLaura Simons, Lina Alasfar, Muath Qadoura, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Pageof 66

Showing results (411-420 of 651) with videos related to

Sort By:
Pageof 66
Blood|January 10, 2024
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signatureAnna Mathioudaki, Xizhe Wang, David Sedloev, et al.
Plos One|October 8, 2016
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid LeukemiaChristoph Schliemann, Joachim Gerss, Stefanie Wiebe, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Cytotherapy|March 27, 2019
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cellsLei Wang, Wenjie Gong, Sanmei Wang, et al.
Blood Advances|June 12, 2026
High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCTJoseph Kauer, Isabelle Krämer, Patrick Derigs, et al.
Journal of Medicinal Chemistry|March 19, 2013
Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factorChristian Schwöppe, Caroline Zerbst, Max Fröhlich, et al.
European Journal of Haematology|September 24, 2017
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patientsSabine Kayser, Maximilian Feszler, Julia Krzykalla, et al.
Blood Vessels, Thrombosis & Hemostasis|December 3, 2025
Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkersLaura Simons, Lina Alasfar, Muath Qadoura, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Pageof 66